ATE348099T1 - Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden - Google Patents
Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor ligandenInfo
- Publication number
- ATE348099T1 ATE348099T1 AT02714914T AT02714914T ATE348099T1 AT E348099 T1 ATE348099 T1 AT E348099T1 AT 02714914 T AT02714914 T AT 02714914T AT 02714914 T AT02714914 T AT 02714914T AT E348099 T1 ATE348099 T1 AT E348099T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- dopamine
- compounds
- urea derivatives
- receptors
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract 4
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 230000000142 dyskinetic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 201000006152 substance dependence Diseases 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26965401P | 2001-02-16 | 2001-02-16 | |
| GBGB0117950.6A GB0117950D0 (en) | 2001-02-16 | 2001-07-23 | Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE348099T1 true ATE348099T1 (de) | 2007-01-15 |
Family
ID=26246345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02714914T ATE348099T1 (de) | 2001-02-16 | 2002-02-15 | Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1392676B1 (de) |
| JP (1) | JP4497814B2 (de) |
| AT (1) | ATE348099T1 (de) |
| CA (1) | CA2438316A1 (de) |
| DE (1) | DE60216753T2 (de) |
| DK (1) | DK1392676T3 (de) |
| ES (1) | ES2275853T3 (de) |
| IL (1) | IL157363A0 (de) |
| MX (1) | MXPA03006843A (de) |
| WO (1) | WO2002066468A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60318891T2 (de) * | 2002-12-13 | 2009-01-22 | Smithkline Beecham Corp. | Cyclopropylverbindungen als ccr5 antagonisten |
| AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| DE102004021637A1 (de) * | 2004-05-03 | 2005-12-01 | Merck Patent Gmbh | Dihydrobenzothiophene |
| KR20070047763A (ko) * | 2004-07-20 | 2007-05-07 | 시에나 바이오테크 에스.피.에이. | 알파7 니코틴성 아세틸콜린 수용체의 조절제 및 그의치료적 용도 |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| JP5602250B2 (ja) | 2010-01-14 | 2014-10-08 | ノバルティス アーゲー | 副腎ホルモン修飾剤の使用 |
| CN105367565B (zh) * | 2014-08-20 | 2018-10-02 | 上海医药工业研究院 | 哌嗪(啶)环己基衍生物及其治疗精神神经疾病的应用 |
| WO2018021447A1 (ja) | 2016-07-28 | 2018-02-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物 |
| JP7017797B2 (ja) * | 2017-02-24 | 2022-02-09 | 深▲チェン▼市霊蘭生物医薬科技有限公司 | 新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用 |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| CA3089498A1 (en) | 2018-01-26 | 2019-08-01 | Shionogi & Co., Ltd. | Condensed ring compounds having dopamine d3 receptor antagonistic effect |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU221315B1 (en) * | 1989-04-22 | 2002-09-28 | Wyeth John & Brother Ltd | Alkyl-substituted piperazine derivatives, pharmaceutical compositions containing them, and process for producing them |
| KR0173310B1 (ko) * | 1989-04-22 | 1999-02-01 | 폴 에이 리쳐 | 피페라진 유도체 |
| DK181190D0 (da) * | 1990-07-30 | 1990-07-30 | Lundbeck & Co As H | 3-aryl-indol- eller 3-aryl-indazolderivater |
| US5395835A (en) * | 1994-03-24 | 1995-03-07 | Warner-Lambert Company | Naphthalamides as central nervous system agents |
| EP0732332B1 (de) * | 1995-03-17 | 2001-12-19 | Aventis Pharmaceuticals Inc. | Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung |
| US5659033A (en) * | 1995-09-13 | 1997-08-19 | Neurogen Corporation | N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
| IT1282705B1 (it) * | 1996-02-28 | 1998-03-31 | Recordati Chem Pharm | Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria |
| US5990114A (en) * | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
| US5703235A (en) * | 1996-03-21 | 1997-12-30 | Neurogen Corporation | N-Aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands |
| TW504510B (en) * | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| HK1043360A1 (zh) * | 1999-01-08 | 2002-09-13 | Neurogen Corporation | 1-苯基-4-(1-[2-芳基]环丙基)甲基哌嗉：多巴胺受体配体 |
| DE19922443A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen |
| WO2000077004A1 (en) * | 1999-06-14 | 2000-12-21 | Neurogen Corporation | 1-azatricyclic-4-benzylpiperazines |
-
2002
- 2002-02-15 EP EP02714914A patent/EP1392676B1/de not_active Expired - Lifetime
- 2002-02-15 IL IL15736302A patent/IL157363A0/xx unknown
- 2002-02-15 ES ES02714914T patent/ES2275853T3/es not_active Expired - Lifetime
- 2002-02-15 JP JP2002565982A patent/JP4497814B2/ja not_active Expired - Fee Related
- 2002-02-15 DE DE60216753T patent/DE60216753T2/de not_active Expired - Lifetime
- 2002-02-15 WO PCT/US2002/004560 patent/WO2002066468A2/en not_active Ceased
- 2002-02-15 AT AT02714914T patent/ATE348099T1/de not_active IP Right Cessation
- 2002-02-15 MX MXPA03006843A patent/MXPA03006843A/es active IP Right Grant
- 2002-02-15 CA CA002438316A patent/CA2438316A1/en not_active Abandoned
- 2002-02-15 DK DK02714914T patent/DK1392676T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| IL157363A0 (en) | 2004-02-19 |
| JP4497814B2 (ja) | 2010-07-07 |
| CA2438316A1 (en) | 2002-08-29 |
| ES2275853T3 (es) | 2007-06-16 |
| EP1392676A2 (de) | 2004-03-03 |
| DE60216753D1 (de) | 2007-01-25 |
| DK1392676T3 (da) | 2007-04-10 |
| DE60216753T2 (de) | 2008-01-03 |
| MXPA03006843A (es) | 2003-11-13 |
| WO2002066468A2 (en) | 2002-08-29 |
| EP1392676B1 (de) | 2006-12-13 |
| WO2002066468A3 (en) | 2002-10-17 |
| JP2004518744A (ja) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2253526T3 (es) | Derivados de carbonilo sustituidos heterociclicos y su uso como ligandos de receptores d3 de dopamina. | |
| WO2002066469A3 (en) | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands | |
| CO5370677A1 (es) | Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina | |
| BR0011823A (pt) | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo | |
| BR0207526A (pt) | Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral | |
| DE60216753D1 (de) | Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden | |
| EA200300854A1 (ru) | Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE451368T1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
| EA200702135A1 (ru) | Лечение болезни паркинсона, обструктивного синдрома апноэ во сне, слабоумия с тельцами льюи, сосудистой деменции с помощью не содержащих имидазола алкиламиновых лигандов гистаминовых н3-рецепторов | |
| BR0307504A (pt) | Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal | |
| DE69928521D1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
| CO5390077A1 (es) | Nuevos derivados heterociclicos de urea y su uso como ligantes receptores d3 de dopamina | |
| WO2005062992A3 (en) | Substituted melatonin derivatives, process for their preparation, and methods of use | |
| BR0208241A (pt) | Composto, composições farmacêutica métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção, ou demência de alzheimer, para aumentar a potência de um efeito terapêutico de um agente do cns, para determinar a presença ou ausência de receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, e, uso de um composto | |
| ATE492528T1 (de) | Derivate und pharmazeutische zusammensetzungen von n-hydroxyalkyltetramethyl cyclo propan carboxamid mit antiepileptischer und verfahren zu deren herstellung | |
| DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| PT1192161E (pt) | Cromeno¬4,3,2/de| isoquinolinas como ligandos potentes de receptores de dopamina | |
| DE59808106D1 (de) | Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe | |
| ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
| ID29601A (id) | PENGGUNAAN (+)-α-(2,3-DIMETOKSIFENIL)-1-(2-(4-FLUOROFENIL)ETIL)-4-PIPERIDINMETANOL UNTUK MENGOBATI GANGGUAN TIDUR | |
| ATE338560T1 (de) | Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung | |
| DE60308127D1 (de) | Pharmazeutische Zusammentsetzung zur medizinischen Behandlung von gutartiger prostathyperplasie, dessen Vorbereitungsmethode und dessen therapeutische Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1392676 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |